Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab vs Aflibercept for Post-Injection Inflammation and Pain in nAMD
NCT01926977Phase 2Completed
- Sponsor
- Arshad M. Khanani
- Start
- Sep 2013
- Primary completion
- May 2014
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ranibizumab, aflibercept in neovascular age-related macular degeneration (NVAMD), sponsored by Arshad M. Khanani. Started Sep 2013; status: completed.
02
Drugs
ranibizumabaflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT01926977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01926977.